Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|January 18, 2022
Imputation of Missing Covariates in Randomized Controlled Trials with Continuous Outcomes: Simple, Unbiased and Efficient MethodsMutamba T Kayembe, Shahab Jolani, Frans E S Tan, et al.
Pharmaceutical Statistics|June 9, 2020
Imputation of missing covariate in randomized controlled trials with a continuous outcome: Scoping review and new resultsMutamba T Kayembe, Shahab Jolani, Frans E S Tan, et al.
Scientific Reports|July 2, 2025
Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitorsHanna Saadani, Else A Aalbersberg, Mutamba T Kayembe, et al.
Cancers|February 25, 2023
Online Adaptive MRI-Guided Radiotherapy for Primary Tumor and Lymph Node Boosting in Rectal CancerChavelli M Kensen, Anja Betgen, Lisa Wiersema, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 28, 2024
FGD-PET/CT three months after (chemo)radiotherapy for head and neck squamous cell carcinoma spares considerable number of patients from a salvage neck dissectionArash Navran, Mutamba T Kayembe, Zeno A R Gouw, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 12, 2025
Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trialAnna Liza M P de Leeuw, Frank J P Hoebers, Jordi Giralt, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 18, 2024
A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE)Anna Liza M P de Leeuw, Jordi Giralt, Yungan Tao, et al.
NPJ Breast Cancer|September 9, 2023
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trialSonja Vliek, Florentine S Hilbers, Erik van Werkhoven, et al.
Pageof 1